Tag: DCBs
Drug-coated balloons: A “first-line” treatment for stenosis and vascular access failure...
This advertorial is sponsored by Cardionovum®
Matteo Tozzi (Varese, Italy) recently spoke to Vascular News about the role of drug-coated balloons (DCBs) in vascular access.
The...
Connect the world session at LINC 2023 projects “outstanding” first-release data...
The Connect The World Session: Japan at this year’s Leipzig Interventional Course (LINC 2023, 6–9 June, Leipzig, Germany)—in collaboration with the Japanese Endovascular...
New analysis: Four multicentre trials support primary use of DCBs over...
A patient-level, propensity-adjusted comparison of three-year results from a quartet of prospective, multicentre trials support the primary use of drug-coated balloons (DCBs) versus bare...
Two-year Ranger DCB data demonstrate “sustained, high rate” of device efficacy
Patients treated with the Ranger drug-coated balloon (DCB; Boston Scientific) sustained “improved primary patency” with fewer reinterventions than those treated with uncoated devices, two-year...
IN.PACT AV DCB sustained “superior” effectiveness in subgroups with high reintervention...
Several subgroups of patients treated with the IN.PACT AV drug-coated balloon (DCB; Medtronic) for arteriovenous fistulas (AVFs) demonstrated a “statistically significant” higher rate of...
Episode 2: Are all peripheral drug-coated balloons created equal?
“Not all Drug-Coated Balloons (DCBs) are created equal”, Juan Granada (New York, USA), tells Vascular News in this second episode of a five-part series on the history of DCBs.
Granada discusses why there...
A New DCB Era of Safety and Efficacy
In this supplement: -SAFEPAX: No drug coating pitfalls -Why the RAPID trial is of clinical importance for a paradigm shift -Vascular access rescue with...
